| abstract |
This invention relates to compounds which are generally prostaglandins I2 (IP) receptor modulator, particularly IP receptor antagonists, and which are represented by the general formula wherein A, R1 and R2 are defined in the specification; and individual isomers, racemic or non-racemic mixture of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, a process for the preparation of such compounds and their use for treating diseases associated with pain, inflammation, urinary tract disease states, respiratory disease states, edema formation, or hypotensive vascular diseases. 22 claims |